C12N 2830/34
Being a transcription initiation element
Official title: being a transcription initiation element
C12N2830/34 (Being a transcription initiation element) appears on 44 US grants and 173 published applications in this corpus.
Search patents in C12N- Granted patents
- 44
- Published applications
- 173
- Assignees
- 136
- Inventors
- 577
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 1 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 1 | 1 |
| 2006 | 0 | 0 |
| 2007 | 1 | 0 |
| 2008 | 0 | 4 |
| 2009 | 0 | 1 |
| 2010 | 0 | 5 |
| 2011 | 3 | 1 |
| 2012 | 2 | 2 |
| 2013 | 0 | 2 |
| 2014 | 1 | 0 |
| 2015 | 1 | 4 |
| 2016 | 1 | 7 |
| 2017 | 4 | 5 |
| 2018 | 3 | 2 |
| 2019 | 4 | 3 |
| 2020 | 2 | 6 |
| 2021 | 1 | 1 |
| 2022 | 2 | 5 |
| 2023 | 1 | 8 |
| 2024 | 5 | 1 |
| 2025 | 5 | 11 |
| 2026 | 7 | 103 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Promoter and use thereof15 Sep 2026US 12,735,715 B2Cj Cheiljedang Corporation
- Methods and compositions for treating glycogen storage diseases28 Jul 2026US 12,692,512 B2Ultragenyx Pharmaceutical Inc.
- Biologic agents and methods of use7 Jul 2026US 12,673,068 B2Sono Thera, Inc.
- Regulatable adeno-associated virus (AAV) vector2 Jun 2026US 12,642,869 B2Georg-August-UniversitäT GöTtingen Stiftung öFfentlichen Rechts, UniversitäTsmedizin
- Multivalent HVT vector vaccine31 Mar 2026US 12,589,147 B2Intervet Inc.
- Kinetically controlled methods to prepare concentrated shelf-stable nucleic acid transfection vehicles8 Oct 2026US 2026/0308631 A1The Johns Hopkins University
- Single-sex chicken with toxin-antitoxin system1 Oct 2026US 2026/0293865 A1New York University
- Modulation of b-cell translocation gene 1 (btg1) for use in adoptive cell therapy1 Oct 2026US 2026/0294968 A1Baylor College of Medicine
- Dual aav vectors for treating stargardt disease1 Oct 2026US 2026/0295092 A1Atsena Therapeutics, Inc.
- Nannochloropsis-producing viruses and methods and compositions for making the same1 Oct 2026US 2026/0297502 A1Insmed Incorporated
Most cited
By later US patents
- DNA transfection system for the generation of infectious influenza virus91US 6,951,754 B2St. Jude Children?S Research Hospital · 2005
- Orthogonal Cas9 proteins for RNA-guided gene regulation and editing86US 9,587,252 B2President and Fellows of Harvard College · 2017
- Orthogonal Cas9 proteins for RNA-guided gene regulation and editing45US 10,329,587 B2President and Fellows of Harvard College · 2019
- DNA transfection system for the generation of infectious influenza virus45US 7,312,064 B2St. Jude Children's Research Hosptal · 2007
- DNA-transfection system for the generation of infectious influenza virus41US 7,972,843 B2St. Jude Children?S Research Hospital · 2011